Retrophin Reportedly Considers Bid For Raptor Pharma

(RTTNews) - Retrophin Inc. (RTRX), the pharmaceutical company founded by controversial entrepreneur Martin Shkreli, is considering the acquisition of Raptor Pharmaceutical Corp. (RPTP), Bloomberg reported citing people familiar with the matter.

No final agreement has been reached and the companies could decide against a deal. Raptor has also attracted interest from other drugmakers, the report said.

RPTP closed Wednesday's regular trading at $6.90, up $0.37 or 5.67 percent. In the after-hours trade, the stock further gained $0.97 or 14.06 percent.

Shkreli was arrested in December and accused of defrauding investors in hedge funds he ran and of using $11 million of Retrophin assets to pay them off. Shkreli has pleaded not guilty to the charges.